FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617485000> ?p ?o ?g. }

• W2617485000 endingPage "H236" @default.
• W2617485000 startingPage "H224" @default.
• W2617485000 abstract "Myocardial infarction (MI) results in loss of cardiomyocytes, adverse extracellular matrix (ECM) and structural remodeling, and left ventricular (LV) dilation and dysfunction. Tissue inhibitors of metalloproteinase (TIMPs) inhibit matrix metalloproteinases (MMPs), the main regulators of ECM turnover. TIMPs also have MMP-independent functions. TIMP3 levels are reduced in the heart within 24 h of MI in mice. We investigated if overexpression of TIMP3 post-MI limits adverse remodeling and LV dilation and dysfunction. MI was induced by left anterior descending coronary artery ligation in 10- to 12-wk-old male C57BL/6J mice, and adenoviral constructs expressing human (h)TIMP3 (Ad-hTIMP3) or no TIMP (Ad-Null) were injected in the peri-infarct zone (5.4 × 10 7 plaque-forming units/heart, 5 injections/heart). Cardiac function assessed by echocardiography showed improved LV physiology and reduced LV dilation after TIMP3 overexpression compared with the Ad-Null-MI group. Post-MI adverse remodeling was attenuated in the Ad-hTIMP3-MI group, as assessed by greater cardiomyocyte density, less infarct expansion, and ECM disruption. TIMP3 overexpression blunted the early rise in proteolytic activities post-MI. A higher density of coronary arteries and a greater number of proliferating endothelial cells were detected in the infarct and peri-infarct regions in the Ad-hTIMP3-MI group compared with the Ad-Null-MI group. In vitro three-dimensional angiogenesis assay confirmed that recombinant TIMP3 promotes angiogenesis in human endothelial cells, although biphasically and in a dose-dependent manner. Intriguingly, overexpression of Ad-hTIMP3 at 10-fold higher concentration had no beneficial effects, consistent with antiangiogenic effects of TIMP3 at higher doses. In conclusion, optimal overexpression of TIMP3 can be a promising therapeutic approach to limit adverse post-MI remodeling by dually inhibiting early proteolysis and promoting angiogenesis. NEW & NOTEWORTHY Here, we report that tissue inhibitor of metalloproteinase 3 overexpression after myocardial infarction improves myocardial structural remodeling and function by promoting angiogenesis and inhibiting early proteolysis. This demonstrates the therapeutic potential of preserving the local balance of tissue inhibitor of metalloproteinase 3 in the heart given its diverse functions in modulating different processes involved in the adverse postmyocardial infarction remodeling." @default.
• W2617485000 created "2017-06-05" @default.
• W2617485000 creator A5005155015 @default.
• W2617485000 creator A5009361679 @default.
• W2617485000 creator A5025602974 @default.
• W2617485000 creator A5043131704 @default.
• W2617485000 creator A5073614183 @default.
• W2617485000 creator A5078059598 @default.
• W2617485000 creator A5091348611 @default.
• W2617485000 date "2017-08-01" @default.
• W2617485000 modified "2023-10-10" @default.
• W2617485000 title "Myocardial overexpression of TIMP3 after myocardial infarction exerts beneficial effects by promoting angiogenesis and suppressing early proteolysis" @default.
• W2617485000 cites W16158435 @default.
• W2617485000 cites W1691303215 @default.
• W2617485000 cites W1876721594 @default.
• W2617485000 cites W1969504843 @default.
• W2617485000 cites W1977111128 @default.
• W2617485000 cites W2008587727 @default.
• W2617485000 cites W2017049923 @default.
• W2617485000 cites W2019070835 @default.
• W2617485000 cites W2022391569 @default.
• W2617485000 cites W2031280751 @default.
• W2617485000 cites W2041050431 @default.
• W2617485000 cites W2042800560 @default.
• W2617485000 cites W2045517487 @default.
• W2617485000 cites W2051250848 @default.
• W2617485000 cites W2053060883 @default.
• W2617485000 cites W2061511179 @default.
• W2617485000 cites W2083481797 @default.
• W2617485000 cites W2097105593 @default.
• W2617485000 cites W2102666125 @default.
• W2617485000 cites W2107497968 @default.
• W2617485000 cites W2107726585 @default.
• W2617485000 cites W2110512943 @default.
• W2617485000 cites W2124693576 @default.
• W2617485000 cites W2130483595 @default.
• W2617485000 cites W2130674647 @default.
• W2617485000 cites W2130861377 @default.
• W2617485000 cites W2134213199 @default.
• W2617485000 cites W2137365872 @default.
• W2617485000 cites W2139063104 @default.
• W2617485000 cites W2139068414 @default.
• W2617485000 cites W2142285130 @default.
• W2617485000 cites W2145233450 @default.
• W2617485000 cites W2145899271 @default.
• W2617485000 cites W2147217262 @default.
• W2617485000 cites W2151432595 @default.
• W2617485000 cites W2166859762 @default.
• W2617485000 cites W2167442950 @default.
• W2617485000 cites W2168048360 @default.
• W2617485000 cites W2171130322 @default.
• W2617485000 cites W2266017856 @default.
• W2617485000 cites W2515791210 @default.
• W2617485000 cites W2516624169 @default.
• W2617485000 cites W4249896096 @default.
• W2617485000 cites W4293084779 @default.
• W2617485000 doi "https://doi.org/10.1152/ajpheart.00108.2017" @default.
• W2617485000 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28550172" @default.
• W2617485000 hasPublicationYear "2017" @default.
• W2617485000 type Work @default.
• W2617485000 sameAs 2617485000 @default.
• W2617485000 citedByCount "47" @default.
• W2617485000 countsByYear W26174850002017 @default.
• W2617485000 countsByYear W26174850002018 @default.
• W2617485000 countsByYear W26174850002019 @default.
• W2617485000 countsByYear W26174850002020 @default.
• W2617485000 countsByYear W26174850002021 @default.
• W2617485000 countsByYear W26174850002022 @default.
• W2617485000 countsByYear W26174850002023 @default.
• W2617485000 crossrefType "journal-article" @default.
• W2617485000 hasAuthorship W2617485000A5005155015 @default.
• W2617485000 hasAuthorship W2617485000A5009361679 @default.
• W2617485000 hasAuthorship W2617485000A5025602974 @default.
• W2617485000 hasAuthorship W2617485000A5043131704 @default.
• W2617485000 hasAuthorship W2617485000A5073614183 @default.
• W2617485000 hasAuthorship W2617485000A5078059598 @default.
• W2617485000 hasAuthorship W2617485000A5091348611 @default.
• W2617485000 hasBestOaLocation W26174850001 @default.
• W2617485000 hasConcept C109523444 @default.
• W2617485000 hasConcept C126322002 @default.
• W2617485000 hasConcept C164705383 @default.
• W2617485000 hasConcept C179437574 @default.
• W2617485000 hasConcept C189165786 @default.
• W2617485000 hasConcept C2775965246 @default.
• W2617485000 hasConcept C2779537366 @default.
• W2617485000 hasConcept C2780394083 @default.
• W2617485000 hasConcept C500558357 @default.
• W2617485000 hasConcept C55728118 @default.
• W2617485000 hasConcept C71924100 @default.
• W2617485000 hasConcept C86803240 @default.
• W2617485000 hasConcept C95444343 @default.
• W2617485000 hasConceptScore W2617485000C109523444 @default.
• W2617485000 hasConceptScore W2617485000C126322002 @default.
• W2617485000 hasConceptScore W2617485000C164705383 @default.
• W2617485000 hasConceptScore W2617485000C179437574 @default.
• W2617485000 hasConceptScore W2617485000C189165786 @default.
• W2617485000 hasConceptScore W2617485000C2775965246 @default.
• W2617485000 hasConceptScore W2617485000C2779537366 @default.

• next